The landscape of regulated plant extracts is evolving rapidly in Europe, particularly with regard to hemp and CBD. While there isn't, strictly speaking, a single text that perfectly embodies the idea of a "new framework" encompassing market, healthcare, and roadside monitoring, recent developments demonstrate a complex web of regulations that are fundamentally reshaping the conditions of production, import, marketing, and control. By 2026, this area will primarily fall under internal market law, food safety regulations, novel food regulations, and, depending on the specific product, cosmetic or pharmaceutical law.
The term "roadside control" also warrants clarification. Recent sources primarily refer to compliance checks, traceability, product safety, and legal qualifications, rather than a separate roadside control regime specific to plant extracts. To understand this new framework for regulated plant extracts, it is therefore necessary to distinguish between the uses, concentrations, claims, distribution channels, and analytical requirements that govern market access.
A fragmented but increasingly structuring European framework
The first lesson from recent texts and documents is simple: there is no single regulatory framework for plant extracts, but rather several layers of regulations. The same extract can change its regulatory status depending on its final use. If it is intended for food, it may fall under the regulations for novel foods; if it is marketed for skincare, it may fall under cosmetic regulations; and if it is intended for therapeutic use with a prescription or medical claim, pharmaceutical regulations come into play.
This multiplicity of classifications explains why the market remains fluid. The European Commission, EFSA, EUDA, and national regulations do not all examine products from the same perspective. For operators, the challenge is not simply to sell a plant extract, but to demonstrate which regulatory category it falls into, what safety evidence it provides, in which Member State, and for what specific use.
In practice, this "new framework" should therefore be understood as a set of converging rules. It is not a single, centralized reform, but rather a gradual tightening of requirements regarding composition, traceability, analysis, claims, and technical documentation. This is particularly true for hemp extracts, which have become a regulatory benchmark for the entire sector of sensitive plant extracts.
Hemp and CBD: a growing market under scrutiny
The European Commission points out that hemp, i.e., Cannabis sativa L., is a species with very low THC content when grown through authorized channels. In 2024, 116 hemp varieties were registered in the European Union's common catalogue, illustrating the agricultural and economic importance of this plant at the European level. The market is no longer limited to fibers or traditional industrial uses: hemp extracts and CBD are now generating significant interest in the food and wellness sectors.
This economic momentum, however, is hampered by strict regulations. The 0.3% THC threshold remains a key reference point in European trade, particularly for imports of raw hemp falling under code CN 5302 10. The Commission also emphasizes that these imports are subject to licensing, demonstrating that hemp, despite being integrated into an agricultural context, remains monitored as a sensitive raw material.
For companies, market growth does not mean total freedom. The rise of CBD and its derivatives is accompanied by an increased need for documentary evidence, reliable analytical results, and continuous vigilance regarding regulatory thresholds. As demand increases, authorities increasingly require a clear distinction between agricultural products, processed extracts, food ingredients, cosmetics, and medicinal preparations.
The new food lock in 2026
The most significant factor for the food market remains the novel food regime as defined by Regulation (EU) 2015/2283. In 2026, the authorization procedure remains active for several hemp-related products, as demonstrated by the European Commission's monitoring of procedure closure decisions. In other words, the sector is not yet stable: applications continue to be processed, and market access still depends on highly detailed safety assessments.
The opinion issued by EFSA on March 30, 2026, regarding a CO₂ extract of Cannabis sativa L. clearly illustrates this requirement. The agency considered that the product's safety could not be established under the proposed conditions of use due to a lack of adequate data, particularly concerning the stability and toxicology of a representative sample. This opinion does not prohibit all innovation, but it serves as a reminder that the absence of robust evidence prevents authorization.
For operators, the lesson is twofold. On the one hand, an innovative plant extract cannot be launched solely on the basis of its commercial appeal or natural origin. On the other hand, the authorities expect robust data, based on representative samples and credible analytical methods. Novel food regulations thus become a crucial filter for hemp extracts intended for food use.
Care, well-being and medical use: decisive legal boundaries
Regulated plant extracts often occupy a gray area between wellness, care, and health. This is particularly true for CBD, whose legal classification remains crucial for market access. A useful reminder can be found in a case referred to the CJEU and published in 2026: cannabidiol is indeed a natural substance found notably in hemp, but its regulatory status depends on its method of incorporation, its presentation, and its declared use.
In the field of healthcare, the distinction between cosmetics and medicines is essential. A product applied to the skin without a therapeutic claim will not be subject to the same regulations as a preparation presented to relieve a symptom or treat a disease. Commercial claims are therefore far from being secondary: they determine the legal classification and, consequently, all applicable obligations.
Regarding cannabis-based medicinal products, EUDA points out that there is no uniform centralized authorization for all Member States. Some countries allow access to medicinal preparations through an exception to EU pharmaceutical legislation when a product is prescribed to an individual patient. This confirms that the "healthcare" aspect of the new framework remains highly dependent on national choices, even within a European environment harmonized on certain principles.
What exactly does “roadside checks” entail in this context?
In public discourse, the term "roadside checks" might suggest the existence of specific and unified regulations governing the movement of plant extracts. However, recent sources do not indicate the existence of such an independent legal framework for these products. The most concrete area is that of regulatory control in its broadest sense: conformity checks of goods, sanitary controls, document verification, product classification, and compliance with applicable thresholds.
In other words, when a product is in circulation, the essential questions primarily concern its legal status, labeling, content of regulated substances, commercial purpose, and traceability. In the case of hemp and cannabinoid-rich extracts, control focuses more on product compliance than on the existence of a specialized traffic police force for plant extracts. The physical movement of the product is merely one aspect of broader market control.
This nuance is important for professionals. Talking about "roadside checks" is not wrong if we are referring to checks carried out during transport or distribution, but this should not obscure the essential point: the heart of the system lies in the rules for placing on the market, the composition analyses, the import licenses where applicable, and the operator's ability to justify the exact status of their product.
Sanitary, phytosanitary and analytical compliance controls
It is also important to distinguish between controls related to plant health and those concerning the safety and conformity of processed extracts. In France, the decree of September 3, 1990, concerning the sanitary control of plants and plant products, remains a frequently cited reference for phytosanitary matters. It addresses plant health, their movement, and certain biological risks, but it is distinct from the marketing regulations for extracts intended for food, cosmetics, or personal care.
This distinction is often misunderstood. A plant material may be compliant from a phytosanitary standpoint while still raising questions regarding its food safety, toxicology, or commercial viability. Conversely, a product that is well-presented from a marketing perspective may be insufficiently documented analytically. The new framework for regulated plant extracts therefore requires a sequential analysis: plant origin, processing, final composition, claimed use, and compliance of the dossier.
Compliance checks focus particularly on regulated or high-risk compounds. In the case of plant extracts, this often involves targeted analytical testing: cannabinoids for hemp, phototoxic substances for certain oils or extracts, contaminants, residual solvents, or other compounds of toxicological interest. Traceability becomes a practical cornerstone here, as it links the analyzed batch, the method used, and the product actually placed on the market.
Chemical precursors and stricter controls in 2026
The regulatory strengthening implemented in 2026 concerns not only the plant extracts themselves, but also the control environment in which they circulate. The European Commission has adopted a measure covering nine high-risk chemical precursors. Published in April 2026, this regulation is set to apply from September 18, 2026, following a four-month transition period.
While this text does not directly target all plant extracts, it reflects a general trend: European authorities want to better regulate sensitive substances, supply chains, and uses that may present a risk. For operators, this means increased expectations regarding vigilance, documentation, and knowledge of the inputs or manufacturing processes used.
This context reinforces the idea that compliance is no longer limited to the finished product. Companies must also monitor raw materials, solvents, extraction processes, logistics flows, and the overall consistency of their documentation. In a market where the line between natural ingredient and highly processed product can be thin, the regulatory approach becomes decidedly systemic.
What companies need to remember to secure their market entry
For stakeholders in the sector, the first priority is to correctly classify the product before even considering its commercialization. It is essential to determine whether it is a food ingredient, a novel food, a cosmetic, a medicinal preparation, or a product related to another specific diet. This step determines all subsequent steps: the required evidence, the competent authorities, labeling, authorized claims, and distribution strategy.
The second priority is analytical. Regulated plant extracts, especially those derived from hemp, require precise and repeatable assays. The 0.3% THC threshold remains a key benchmark in EU trade for raw hemp, and more broadly, authorities expect clear composition profiles, traceable results, and stability or safety data appropriate for the product's end use.
Finally, the third priority is documentation. In the context of 2025-2026, a promising market is not enough: it is essential to be able to demonstrate product conformity at each stage. Technical documentation, varietal origin, batch analyses, quality procedures, justification of claims, and consistency of intended use have become the true keys to market access for regulated plant extracts.
Ultimately, the "new framework" for regulated plant extracts doesn't refer to a single text, but rather to a convergence of European and national rules concerning the market, safety, novel foods, hemp-based products, and compliance controls. The case of CBD and Cannabis sativa L. demonstrates that economic demand remains strong, but that it now operates within a much more demanding environment regarding evidence, qualification, and traceability.
For professionals and observers alike, a proper understanding of the issue therefore requires moving beyond the literal interpretation of "roadside checks." By 2026, the central challenge will be a comprehensive control of product circulation on the market: sanitary control, analytical control, documentary control, and legal control. It is this framework, more than the existence of a single, isolated regulation, that now defines the true context for regulated plant extracts.
